Enliven CFO sells 6,018 shares around $59

Enliven Therapeutics, Inc. (ELVN) reported that its Chief Financial Officer, Benjamin Hohl, sold shares of the company’s Common Stock in two open-market transactions on August 17, 2026.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) reported that its Chief Financial Officer, Benjamin Hohl, sold shares of the company’s Common Stock in two open-market transactions on August 17, 2026. He sold 4,630 shares at a weighted average price of $58.3517 per share and 1,388 shares at a weighted average price of $59.3536 per share, totaling 6,018 shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. A portion of the securities associated with his holdings are restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock, subject to vesting conditions.

Insider Trade Summary 10b5-1

Net Seller: 6,018 shares

Net Sell 2 txns

Insider Hohl Benjamin

Role CHIEF FINANCIAL OFFICER

Sold 6,018 shs ($353K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	4,630	$58.3517	$270K
Sale	Common Stock F1, F4, F3	1,388	$59.3536	$82K

Holdings After Transaction: Common Stock — 40,036 shares (Direct)

Footnotes (4)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
2. F2. This transaction was executed in multiple trades at prices ranging from $57.895 to $58.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
4. F4. This transaction was executed in multiple trades at prices ranging from $58.945 to $59.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold (first transaction): 4,630 shares Price per share (first transaction): $58.3517 per share Trade price range (first transaction): $57.895 to $58.89 +5 more

8 metrics

Shares sold (first transaction) 4,630 shares Common Stock sale on August 17, 2026 at weighted average price

Price per share (first transaction) $58.3517 per share Weighted average sale price for 4,630-share transaction

Trade price range (first transaction) $57.895 to $58.89 Multiple trades comprising the 4,630-share sale

Shares sold (second transaction) 1,388 shares Common Stock sale on August 17, 2026 at weighted average price

Price per share (second transaction) $59.3536 per share Weighted average sale price for 1,388-share transaction

Trade price range (second transaction) $58.945 to $59.60 Multiple trades comprising the 1,388-share sale

Total shares sold 6,018 shares Combined sales by CFO on August 17, 2026

Rule 10b5-1 plan adoption date March 18, 2026 Adoption date of trading plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units (RSUs), contingent right

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

restricted stock units (RSUs) financial

"Certain of these securities are restricted stock units (RSUs)."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

contingent right financial

"Each RSU represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ELVN report for CFO Benjamin Hohl on August 17, 2026?

Enliven Therapeutics’ CFO Benjamin Hohl reported selling a total of 6,018 shares of Common Stock on August 17, 2026 in two open-market transactions at weighted average prices near $58–$59 per share.

How many Enliven Therapeutics (ELVN) shares did the CFO sell in each trade?

On August 17, 2026, the CFO sold 4,630 shares at a weighted average price of $58.3517 and 1,388 shares at a weighted average price of $59.3536, for a combined total of 6,018 shares.

Were the August 17, 2026 ELVN insider sales made under a Rule 10b5-1 plan?

Yes. The reported sales by Enliven Therapeutics’ CFO were effected pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026, indicating they followed a pre-established trading schedule.

What price ranges applied to the ELVN shares sold by the CFO on August 17, 2026?

The 4,630-share sale executed in multiple trades had prices ranging from $57.895 to $58.89. The 1,388-share sale had trade prices ranging from $58.945 to $59.60, with reported prices reflecting weighted averages.

Does the ELVN Form 4 mention restricted stock units (RSUs) for the CFO?

Yes. The filing notes that certain securities are restricted stock units (RSUs), each representing a contingent right to receive one share of Enliven Therapeutics Common Stock, subject to vesting schedules and conditions attached to each RSU award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 04:18 PM Accepted by SEC EDGAR 08/19/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hohl Benjamin

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S(1)		4,630	D	$58.3517(2)	41,424(3)	D
Common Stock	08/17/2026		S(1)		1,388	D	$59.3536(4)	40,036(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.

2. This transaction was executed in multiple trades at prices ranging from $57.895 to $58.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

4. This transaction was executed in multiple trades at prices ranging from $58.945 to $59.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Benjamin Hohl	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)